Business partnerships with impact
Join us in a strategic partnership to help deliver vital services and support for more than 150,000 Australians living with blood cancer.
We can create a tailored partnership that aligns with your objectives, generates brand awareness, improves employee engagement, grows customer advocacy and delivers social value for the community.
Your environmental and social governance (ESG) strategy is more important than ever before. Consumers, shareholders and employees are demanding companies change the way they do business and use ESG strategies to improve sustainability and transparency.
Research reveals that 67% of Australians see corporates as having as much responsibility for solving society’s problems, as government. And an even higher percentage 76% believe that companies should step in and help charities amid the cost-of-living crisis.
Remarkable Partnerships
Need help?
Environmental and social governance strategies
Let’s work together to achieve your ESG goals and build on a shared purpose to support people with blood cancer.
The Leukaemia Foundation is one of Australia’s most reputable charities* and the next decade has to include big, bold actions to improve treatments, support and outcomes for people with blood cancer. In close collaboration with our valued partners, we’ll continue advocating for greater disease awareness and systemic change in health systems across the country
*Source: 2023 Australian Charity RepTrack Report
Partner with us
Together we can realise a future where no life is lost to blood cancer.
The Leukaemia Foundation funds innovative research and provides wraparound care and support for people with blood cancer across Australia. We encourage our business partners to align investments with their preferred areas of interest including:
What your partnership will support
Practical services
Reduce the burden and stress of a diagnosis by providing people with blood cancer and their families with accommodation, transport, financial assistance and access to our supportive healthcare professionals.
High impact research
Fund life-saving research to:
- Improve quality of life and long-term care for people living with blood cancer
- Save lives by driving innovation in diagnostics, treatment and care
- Provide access to leading-edge clinical trials in Australia and overseas
Survivorship and quality of life
Ensure people are supported through every stage of their cancer journey with education, coaching, counselling and the Leukaemia Foundation’s on-line support service.
Getting started
How to get involved
Working together, we can transform care for people with blood cancer.
Partnerships can be designed to align with the unique needs and interests of your business.
Sponsor a key fundraising campaign or offer goods and services with in-kind support.
Sponsorships
Encourage employees to donate directly through payroll.
Workplace giving
committed to improving research, services and care for people with blood cancer.
Meet our current partners
Improve employee engagement through fundraising activities.
Fundraising
Together we can make Project 2035 a reality
Supported by leading businesses, Project 2035 is a bold and ambitious project committed to reducing preventable blood cancer deaths to zero by 2035. By becoming part of Project 2035, you will drive innovation forward, revolutionise patient support and shape the direction of leading-edge research.
Blood Cancers A-Z
A
AA secondary amyloidosis
Acute lymphoblastic leukaemia ALL
Acute myeloid leukaemia AML
Acute myelomonocytic leukaemia AMML
Acute promyelocytic leukaemia APML
Afib mutated fibrinogen alpha chain amyloidosis
AL systemic amyloidosis
Amyloidosis
Aplastic anaemia AA
ATTR familial amyloidotic polyneuropathy
ATTR wild type senile amyloidosis
B
Biphenotypic leukaemia
Bisphosphonates myeloma
C
Chronic lymphocytic leukaemia CLL
Chronic myeloid leukaemia CML
H
Hairy cell leukaemia
Hodgkin lymphoma
I
IgA myeloma
IgG myeloma
J
Juvenile myelomonocytic leukaemia JMML
L
Langerhans Cell Histiocytosis LCH
Leukaemia
Light chain myeloma
Lymphocyte depleted HL
Lymphocyte rich HL
Lymphoma
M
MDS with biallelic TP53 inactivation MDS-biTP53
MDS with fibrosis
MDS with hypoplastic MDS-h
MDS with increased blasts MDS-IB1
MDS with increased blasts MDS-IB2
MDS with low blasts MDS-LB
MDS with low blasts and isolated 5q deletion MDS-5q
MDS with low blasts and SF3B1 mutation MDS-SF3B1
Mixed cellularity HL
Monoclonal gammopathy of unknown significance MGUS
MPN Chronic eosinophilic leukaemia CEL
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic neutrophilic leukaemia CNL
MPN Essential thrombocythaemia ET
MPN Polycythaemia Rubra vera PV
MPN Primary myelofibrosis MF
MPN Systemic mastocytosis SM
Multiple myeloma
Myelodysplasia Myelodysplastic neoplasms MDS
Myeloma
Myeloid sarcoma localised leukaemia
Myeloproliferative neoplasms MPN
N
NHL Adult T-Cell leukaemic ATLL
NHL Anaplastic large cell ALCL
NHL Burkitt’s
NHL Cutaneous T-Cell
NHL Diffuse large B-cell DLBCL
NHL Double hit DHL
NHL Follicular
NHL Lymphoplasmacytic Waldenstrom’s macroglobulinaemia WM
NHL MALT
NHL Mantle cell
NHL Marginal zone
NHL Peripheral T-Cell
NHL Primary cutaneous B-cell
NHL Primary mediastinal B-cell PMBCL
NHL Small lymphocytic SLL
NHL Subcutaneous panniculitis-like T-Cell
NHL T-Lymphoblastic
NHL Waldenstroms macroglobulinaemia
Non-Hodgkin lymphoma
Nodular lymphocyte predominant HL
Nodular sclerosing HL
O
Osteosclerotic myeloma
P
Paroxysmal nocturnal haemoglobinuria
Plasmacytoma localised myeloma
POEMS syndrome
R
Richter’s syndrome leukaemia
S
Smouldering indolent myeloma
Solitary plasmacytoma myeloma
Systemic mastocytosis